PLBD1 and central nervous system cancer: Based on the median risk score of the 9 NRLs with “MIR210HG×(0.076500)+LINC01503×(0.092220)+CRNDE×(0.080224)+WAC-AS1×(-0.119002)+ADRA1-AS1×(-0.422643)+HOXC-AS1×(0.060804)+ZIM2-AS1×(0.203541)+MIR22HG×(0.079291)+PLBD1-AS1×(0.279336)”, 334 glioma patients in the training cohort and glioma patients in CGGA cohort (external validation) as well as 333 in the testing cohort were divided into high- and low-risk groups (Figure 4A–4F).